Medical device company LeMaitre Vascular (NASDAQ: LMAT) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 11.4% year on year to $61.05 million. Next quarter’s revenue guidance of $62.8 million underwhelmed, coming in 2.9% below analysts’ estimates. Its GAAP profit of $0.75 per share was 31.5% above analysts’ consensus estimates.

Is now the time to buy LMAT? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

LeMaitre’s third quarter results drew a negative market reaction as revenue trailed Wall Street expectations, despite solid year-over-year growth. Management cited strong performances from the Grafts and Shunts product lines as key contributors, with organic sales growth driven primarily by price increases rather than unit volume. CEO George LeMaitre pointed out that a recall earlier in the year led some customers to pull forward purchases, limiting Q3 and likely Q4 growth. International expansion, particularly in Europe and South Africa, provided additional momentum, though challenges persisted in the Asia-Pacific region.

Looking to the next quarter, management’s guidance reflects tempered expectations, with leadership highlighting several near-term headwinds. CEO George LeMaitre explained, “The catheter recall is still pulling sales forward, and APAC remains a challenging region due to recent management turnover and market dynamics.” The company is also monitoring foreign currency fluctuations and regulatory approval timelines, particularly in Europe, as factors that could impact growth. Investments in new distribution centers and continued hiring remain priorities, but LeMaitre expects the revenue mix to remain weighted toward biologics and niche products, where pricing power is strongest.

Key Insights from Management’s Remarks

Management attributed Q3’s performance to product mix improvements, robust pricing strategies, and operational efficiencies, while noting disruptions from a recent catheter recall and pressure in Asia-Pacific markets.

• Product mix shift: Growth was led by Grafts (up 23%) and Shunts (up 18%), with biologic products like Artegraft and XenoSure highlighted for their momentum. Management noted that Artegraft’s international launch exceeded internal expectations, particularly due to faster-than-anticipated European and South African market adoption.

• Pricing power and price floors: Price increases accounted for the majority of Q3’s organic growth, with a recently published U.S. hospital price list reflecting an 8% average hike for 2026. CEO George LeMaitre emphasized that 55% of North American revenue is now secured by price floors, which help insulate against competitive pricing pressures in niche categories.

• Operational efficiency gains: Manufacturing automation and improved cost controls contributed to margin expansion. CFO Dorian LeBlanc cited a 300 basis point improvement in adjusted gross margin, driven by higher pricing, manufacturing efficiencies, and favorable product mix.

• Salesforce optimization: A performance-based reduction of eight sales reps was offset by ongoing recruiting, with the company targeting 165 reps by year-end. Management expects further expansion in the U.S. and early-stage growth in China, where current headcount remains low relative to market potential.

• Geographic performance divergence: EMEA (Europe, Middle East & Africa) posted 18% growth, while APAC lagged, hampered by management changes and regional market softness. The Americas saw steady 10% growth, with continued emphasis on expanding direct sales channels in key international markets.

Drivers of Future Performance

LeMaitre’s outlook is shaped by ongoing pricing initiatives, biologics growth, and operational expansion, balanced against lingering recall effects and international uncertainty.

• Biologics and new approvals: Management expects biologics, including Artegraft and XenoSure, to remain key growth drivers, with upcoming regulatory approvals in Germany, Ireland, Canada, and Korea. CEO George LeMaitre indicated that European approvals could accelerate broader international adoption, especially as supply chain constraints are resolved.

• Pricing discipline and margin focus: The company plans to maintain aggressive pricing strategies, particularly in niche segments, while using price floors to protect against margin erosion. Operating margin is expected to remain elevated, supported by cost control and a shift toward higher-margin products, though R&D spending is projected to gradually increase as major regulatory expenses subside.

• Salesforce and geographic expansion: The ongoing buildout of the sales force, particularly in the U.S. and China, is seen as a lever for future growth, with management targeting untapped territories and more direct sales relationships. However, persistent weakness in Asia-Pacific and the need to ramp up local management teams present risks to growth forecasts.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be watching (1) the pace and breadth of biologics adoption, particularly as European and Canadian regulatory approvals come through; (2) the ability to sustain pricing discipline and protect margins amid ongoing cost pressures; and (3) progress toward expanding the sales force in both mature and emerging markets, with a close eye on improvements in the Asia-Pacific region. The resolution of any remaining operational impacts from the catheter recall will also be closely monitored.

LeMaitre currently trades at $83, down from $85.79 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free for active Edge members).

Now Could Be The Perfect Time To Invest In These Stocks

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.